Search Results

CareDx, Inc. today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions, taking place from April 10-13 in Prague, Czech Republic.

TFF Pharmaceuticals, Inc. announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024.

Paragonix Technologies, Inc., a pioneer in organ transplant products and services, is honored to announce the forthcoming release of new clinical data supporting the use of controlled hypothermic preservation and clinical services.

XVIVO Perfusion AB, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO’s clinical trial, NIHP2019, in heart transplantation were presented.

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard®, in the largest real-world multi-center study presented at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease

Natera, Inc. today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, announces the annual release of the latest GUARDIAN-Heart Clinical Registry report, shared earlier today at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease.

Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing.